Along with the reverse merger, Candid Therapeutics announced $505 million in private financing to support its pipeline of T cell engagers for autoimmune disease. Lead program cizutamig is on track to begin global Phase 2 testing in myasthenia gravis and interstitial lung disease.
The post Candid Therapeutics Strikes Up Merger With Rallybio to Advance Its Autoimmune Drug Pipeline appeared first on MedCity News.
